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Spectrum of early onset nephrotic syndrome associated with WT1
missense mutations. We investigated 17 children with nephrotic syndrome
(NS) of early onset (14 aged , 1 year) and rapid progression to end-stage
renal disease for the presence of mutations in the Wilms’ tumor suppres-
sor gene WT1 on chromosome 11. In eight children (7 genotypic males) an
association with Wilms’ tumor and/or ambiguous genitalia (Denys-Drash
syndrome) was observed. In these eight and two additional female patients
with NS only constitutional missense mutations in the WT1 gene were
detected; four children presented the so-called hot spot mutation in exon
9 (R394N) and six had different mutations in exons 8 and 9 (4 not
previously described). Renal biopsy showed diffuse mesangial sclerosis in
eight and focal segmental sclerosis in two cases. End-stage renal disease
was reached either concomitantly or within four months after onset of NS
in seven of ten patients. A unilateral Wilms’ tumor was found before or
concomitant with NS in four children (3 males, 1 female). From the seven
genotypic males with WT1 mutations, five presented ambiguous genitalia
and two a female phenotype. No mutation of the WT1 gene was found in
seven other children with isolated congenital or infantile NS with or
without DMS who appeared to have a slower progression than the first
group. It is proposed that patients with early onset, rapidly progressive NS
and diffuse mesangial or focal segmental sclerosis should be tested for
WT1 mutations to identify those at risk for developing Wilms’ tumor.
The triad of Wilms’ tumor (WT), male pseudohermaphroditism
and progressive glomerulopathy is known as Denys-Drash syn-
drome (DDS) [1, 2]. Subsequent reports described patients with
incomplete forms of this syndrome [3–5] dividing DDS into three
clinical categories: (1) genotypic males with all three abnormali-
ties, (2) genotypic males with nephropathy and ambiguous exter-
nal and/or internal genitalia only, and (3) genotypic females with
nephropathy and WT only. All patients show glomerulopathy,
usually characterized by the histologic finding of diffuse mesangial
sclerosis (DMS) and in rare cases focal segmental glomeruloscle-
rosis (FSGS) is observed [3, 4]. DMS may also be observed as an
isolated sporadic or familial disorder [6]. Clinically DMS is
characterized by massive proteinuria with a nephrotic syndrome
starting early in life and progressing rapidly to end-stage renal
disease (ESRD) [3, 4, 6]. The only difference between isolated
DMS and DMS associated with DDS seems to be the familial
occurrence in the former. WT associated with DDS is more often
bilateral and on the average has an earlier onset than isolated
(sporadic) WT.
WT1, one of the WT suppressor genes was isolated by positional
cloning from chromosome 11p13 [7, 8] and encodes a transcrip-
tion factor of the zinc finger (ZF) family. Four transcripts are
produced by alternative splicing [9, 10]. In WT patients a variety
of mutations in the WT1 gene was described [11]. The WT1 gene
plays a specific role during the embryonic development of the
kidney, genitalia and other organs [12–15]. Mice with a homozy-
gous deletion of WT1 fail to activate the development of the
urogenital system, confirming its key role in this process [16]. The
expression of WT1 in both kidney and urogenital system might
explain that DDS is often associated with a mutation in this gene
[13]. Our review of the literature [17–35; summaries, 11, 35]
showed that among 50 patients with complete or incomplete
forms of DDS 21 different WT1 mutations were found. Most
patients presented the characteristics of DMS as described by
Habib et al [3, 6].
Attempts to correlate the phenotype of DDS and different WT1
mutations did not provide clearcut results. However, these inves-
tigations were often hampered by insufficient accounts of the
clinical and pathoanatomical manifestations and the lack of
reporting comparable patients without WT1 mutations.
The primary aims of this work was (1) to identify mutations of
the WT1 gene in a large spectrum of patients with progressive
forms of early onset NS with or without the clinical diagnosis of
DDS; (2) to correlate the different WT1 mutations with the
phenotype of DDS; and (3) to identify patients with an increased
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risk to develop WT. For this study infants with complete or
incomplete DDS were investigated and patients of the same age
range with isolated NS associated with DMS or other renal




The clinical and pathoanatomic features of 17 children with
early onset NS studied are summarized in Table 1. Three geno-
typic male children had the complete form of DDS and four males
an incomplete form without WT. Five of the seven males had
presented with a NS in the first year of life, corresponding to a
congenital or infantile NS; two had an onset of NS at three years
of age. One of the three females presented with NS at 18 months,
a WT being found concomitantly (NS8).
In addition, we investigated one male and three females with
isolated congenital or infantile NS in absence of a WT or obvious
genital anomalies associated with DMS (NS9-12) and five children
with a similar age at onset but different renal histopathology. Five
of the 17 patients had a family history of progressive NS (NS11,
NS14-NS17) and five had more or less severe extrarenal/extragen-
ital malformations which were missing in the group with WT1
mutations. All 17 except one patient (NS16) developed ESRD;
most were treated with dialysis and subsequently underwent
transplantation. Three patients died (Table 1). Patients with
congenital NS of the Finnish type were excluded from this study.
Molecular methods
Mutations of the WT1 gene were searched for in blood DNA
from the 17 patients listed in Table 1 and from some asymptom-
atic relatives (6 parents, 2 siblings) in four affected families. In
addition, we investigated tumor DNA from one patient obtained
at the time of nephrectomy.
Preparation of genomic DNA. Constitutional DNA was isolated
from blood samples (5 ml) by the SDS-proteinase K method as
described previously [36].
PCR-SSCP analysis of the WT1 gene. We used the single-strand
conformational polymorphism (SSCP) method to analyze all WT1
coding exons for alterations within the germline of patients [37].
All 10 exons were amplified by the polymerase chain reaction
(PCR) from genomic DNA.
Polymerase chain reaction. The sequences of the oligonucleo-
tides were as published [36]. Each PCR reaction contained 100 ng
genomic DNA, 1x Taq DNA Polymerase buffer, 25 pmol of each
primer, 200 mM nucleotides and 1 U Taq Polymerase in a total
volume of 50 ml. Conditions for the different PCRs were as
described previously [36].
Single-strand conformational polymorphism. Following PCR a 1
to 1.5 ml aliquot of the amplified product was diluted with 4 to 4.5
ml 95% formamide, 10 mM EDTA. The DNA samples were
denatured at 95°C for 10 minutes and immediatly placed on ice
before loading on 8% polyacrylamide nondenaturing gels (29:1 or
49:1 acrylamide:bisacrylamide) containing 2% or 10% glycerol.
Electrophoresis was performed in 0.09 M Tris base-0.09 M boric
acid-2 mM EDTA running buffer at 500 Volt at 15°C for two to
four hours. The gels were then silver stained. Every sample was
analyzed using four sets of electrophoresis conditions to maximize
the sensitivity of the technique.
Restriction enzyme analysis. Restriction digests were performed
overnight according to the manufacturers instructions. The DNA
fragments were separated on 3% NuSieve agarose gels and
visualized with ethidium bromide staining.
Direct sequencing of PCR products. Single-stranded sequence
templates were prepared using biotinylated primers and strepta-
vidin coated magnetic beads (Dynal, Norway) according to the
manufacturers recommendation. Dideoxy sequencing was per-
formed using the Sequenase Kit Version 2.0 (US Biochemicals,
USA) and 35S-ATP labeling. The products were separated on 6%
denaturing polyacrylamide gels and exposed to X-ray film over-
night. In one case direct sequencing was performed using the
automated LI-COR sequencer (MWG Biotech).
RESULTS
In 10 of the 17 patients, mutations in the WT1 gene were found.
Four mutations have not been described before (Table 1). All
patients were analyzed for mutations in the WT1 gene using the
SSCP method. First the four exons encoding the four zinc fingers
were analyzed and when no alterations were found the rest of the
gene was analyzed as well. Alterations detected by SSCP were
sequenced and verified if possible by a restriction enzyme digest.
DNAs with known mutations were loaded on the same gel to
check for the presence of these mutations.
The hot spot mutation 394 Arg.Trp in exon 9 (now called
R394W) was found in four patients. Figure 1 shows the SSCP
analysis of three patients and one normal control (NEK). Two
additional bands are seen in the DNA from patients NS1, NS2 and
NS8, when compared to normal NEK DNA. Tumor DNA was
analyzed from patient NS8 and it shows only the altered bands,
demonstrating that the tumor has lost the normal allele. The
mutation abolishes a HpaII restriction enzyme site, and can
therefore be detected by digestion of the PCR products with this
enzyme (Fig. 2). Both, the mutant (undigested) and wild-type
(digested) alleles are seen in blood DNA from patients NS1, NS2
and NS8. This hot spot mutation was observed in two genotypic
males (NS1 and NS2) with complete DDS and one female (NS8)
with incomplete DDS. In addition, it was found in a female
(NS10) with isolated infantile NS, suggesting that this is also a
DDS patient (data not shown).
Three other patients exhibited different mutations in exon 9: (1)
a boy (NS5) with incomplete DDS and a new mutation at the hot
spot location, changing nucleotide 1181 G.A and amino acid
394Arg to Gln, characterized by a very rapid course to ESRD and
FSGS in the renal biopsy; (2) a male patient (NS3) with complete
DDS and a new mutation at nucleotide position 1153 T.C
changing amino acid 385 Cys to Arg (Fig. 3); (3) a male patient
NS4 with incomplete DDS having ambiguous external genitalia
and no Wilms tumor with a mutation changing an amino acid
directly involved in DNA binding (D396N, data not shown).
Three patients had different mutations in exon 8: two genotypic
males, one with ambiguous (NS6) and one with female genitalia
(NS7) but without WT, and a girl with isolated congenital NS and
an advanced form of diffuse glomerular sclerosis leading to ESRD
at the age of three months (NS9). Patient NS7, who had the most
precipitated course in this series, will be reported elsewhere
(Guschmann et al, manuscript submitted). Patients NS6 and NS9
have novel mutations at nucleotide position 1090 T.C and 1135
G.T, respectively. The first of these mutations changes an amino
acid in the binding backbone of the protein and the second
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—
Isolated congenital/Infantile NS associated with different renal histopathology
NS13 46XX F — 2 11 (15) 30 (1.0) 36 — MGN PD-.TX-.HD-.
TX (19.0)
—
NS14b 46XX F, CHD — 1 (.1) 4 (21) 60 79 90/98 MGN HD-.TX (11.0) —
NS 15b 46XX F, CHD — 1 (0.8) 1 (23) 3 (0.6) 40 46 L1R MGN HD-TX (8.7) —






— 4 (13) 4 (8) 5 (1.0) 10 — MC, IF PD (4.3) —
Abbreviations are: DDS, Denys-Drash syndrome; F, normal external female genitalia; M, male genitalia; s. urog., sinus urogenitalis; CHD, congenital
heart disease; Wilms’ tumor: R, right kidney; L, left kidney; tri, mixed triphasic; s, stromal-predominant; Glomerulopathy: SAlb, serum albumin; RF,
renal failure; SCr; serum creatinine; ESRD, end-stage renal disease; NX, nephrectomy; RRT, renal replacement therapy; Histology: DMS, diffuse
mesangial sclerosis; FSGS, focal segmental sclerosis; IF, interstitial fibrosis; MGN, mesangioproliferative glomerulonephritis; MC, minimal glomerular
changes; PD, peritoneal dialysis; HD, hemodialysis; Tx, renal transplantation; AC, amnion cells.
Affected relatives: a sister had CNS/DMS/ESRD; b sisters; c sister had CNS/ESRD/MC; d cousin had CNS/DMS; e Mutations not previously described
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changes amino acid 379 Gly close to the zinc coordinating
histidine into a cysteine. Zinc binds with a higher affinity to
cysteine than to histidine so that it is likely that both mutations
change the structure of the protein and therefore prevent DNA
binding.
Two infants with a female karyotype had an isolated form of
infantile NS associated with DMS only (NS9, NS10). One of them
presented the hot spot mutation and the other a missense
mutation not previously described. The clinical course and patho-
anatomical findings of these two infants were similiar to the DDS
patients: both developed ESRD within a few weeks after discovery
of nephropathy.
In the 10 patients with WT1 mutations the age at apparent onset
of glomerulopathy ranged from the first days of life to 3.2 years.
Renal histopathology in our patients with WT1 mutations showed
DMS in eight cases. A glomerulus from patient NS8 is shown in
Figure 4. The shrunken tuft exhibits diffuse mesangial sclerosis
with prominent matrix expansion. The podocytes on the tuft
surface are inconspicuous. Two cases presented focal segmental
glomerulosclerosis, one at the age of four days (NS5) and the
other at 32 months (NS2) both combined with widespread inter-
stitial fibrosis.
The WTs were detected at variable times in relation to the
glomerulopathy and were always unilateral. In the seven geno-
typic males with WT1 mutations genital findings were character-
ized either by severe hypospadias with cryptorchidism or appar-
ently normal female external genitalia with an uterus and streak
gonads (NS1–NS7).
Upon recognition of WT1 mutations in two genotypic females
with isolated infantile NS (NS9,10) we performed corresponding
molecular studies in another seven NS patients not affected by
WT. In none of the seven patients we found an anomaly of the
WT1 gene (Table 1). Five patients (NS11, NS14 to NS17) had a
family history of progressive NS of early onset in a sibling or
cousin. The sister of NS11, who was not analyzed for WT1
mutations, died early in ESRD from the same disease. Five
children had associated non-renal anomalies affecting the brain,
eyes, heart, muscles and the skeletal system (NS11, NS12, NS14,
NS15, NS17). The most severe malformation syndrome was found
in NS12 with a very early onset of nephropathy and of ESRD. Two
patients with isolated congenital or infantile NS in absence of
WT1 mutations presented with DMS (NS11 and NS12) the others
(NS13 to NS17) had histopathologic findings compatible with
mesangioproliferative glomerulonephritis or minimal glomerular
lesions (Table 1).
The median age at onset of proteinuria was lower in patients
without compared to those with WT1 mutations (1 vs. 6 months),
but the median time from onset to ESRD was shorter in the
patients with mutations (2 vs. 19 months). However, due to the
low number of patients compared from each group this difference
was not statistically significant.
Furthermore, our investigation was supplemented by a group of
six children with idiopathic NS with a late onset steroid resistant
FSGS (between 2.5 and 13 years) that uniformly progressed to
ESRD. None of these patients had a family history of NS or
Fig. 1. Single-strand conformational polymorphism (SSCP) analysis of
WT1 exon 9 from blood (B) DNA of patients NS1, NS2 and NS8. Blood
DNAs show heterozygous mobility pattern compared to the normal
embryonal kidney (NEK) control. In the tumor (T) DNA from patient
NS8 the wild-type allele is lost (only altered bands are seen).
Fig. 2. HpaII digest of WT1 exon 9 from blood DNA of patients NS1, NS2
and NS8 and a normal embryonic kidney (NEK) control. Loss of the
recognition sequence by the mutation results in an undigested fragment of
224 bp; the digested products are 106 and 118 bp. The undigested NEK
control DNA is shown for comparision. M: 1 kb size marker. Schematic
drawing of the mutation with loss of HpaII site and amino acid alteration.
Fig. 3. Sequence analysis of WT1 exon 9 from blood DNA of patient NS3
with the T>C alteration changing amino acid 385Cys to Arg.
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associated anomalies. We failed to find any WT1 mutations by
screening exons 1 to 10 in these patients (data not shown).
No WT1 mutations were detected in the parents of three and
siblings of two patients with DDS or isolated congenital or
infantile NS (see Table 1), demonstrating that these patients had
new germline mutations.
DISCUSSION
Three different types of constitutional mutations have been
described in DDS: missense, nonsense and splicing mutations of
the WT1 gene. Most are missense mutations that involve exon 9
corresponding to the third zinc finger (ZF) of the WT1 gene; less
frequently exons 6, 7 or 8 are affected. An actual review of the
literature [11, 17–35] including our own patients demonstrates
that 40% (24 of 60) of all cases exhibit the hot spot mutation
R394W. Four mutations observed in our investigation were not
described before. One of these changes the amino acid at the hot
spot site directly involved in DNA binding to Gln instead of Trp.
The other three most likely are structural changes of the protein
ultimately also leading to lack of binding to the correct target
sequence [38].
Our study confirms earlier reports that WT1 mutations are
present in children with the classical triad of DDS as well as in
incomplete forms [11], that is, in absence of ambiguous genitalia
or Wilms’ tumor. All the mutations that we describe here are
missense mutations. Similar to earlier studies we also found no
relation between the type of missense mutation and the clinical
phenotype of DDS. However, new genotype/phenotype correla-
tions seem to emerge: (1) our own survey of a large number of
Wilms’ tumor patients with or without genital tract malforma-
tions, revealed that all, except one had nonsense mutations in the
WT1 gene and none of these patients had NS with ESRD ([36],
see below); (2) recently a specific splicing mutation in the WT1
gene was descibed in patients with Frasier syndrome, a rare
disorder defined by male pseudohermaphroditism, progressive
glomerulopathy and often associated with gonadoblastoma but
not Wilms tumor [39]; (3) patients with WT1 missense mutations
always have NS followed by a rapid onset of ESRD associated
with variable expressivity of a Wilms’ tumor and depending on the
primary sex with genital malformations. Therefore, the type of
mutation in the WT1 gene seems to dictate the accompanying
disease, with the following order: a missense mutation causes a
glomerulopathy with ESRD early in life and ambiguous genitalia
in males and a high risk for Wilms tumor and possibly a low risk
for gonadoblastomas; a nonsense mutation causes a high risk for
Wilms tumor and less severe genital tract malformations in males;
a splicing mutation causes glomerulopathy and pseudohermaph-
roditism in males and a moderate risk for gonadoblastoma, but no
risk for Wilms tumor.
A Wilms’ tumor was detected in only four of our ten patients
presenting a WT1 mutation, but it is notable that of the children
without tumor two had died very early and three underwent
bilateral nephrectomy before a WT was detected. One patient
being 3.4 years old at the most recent observation with kidneys left
in situ may still develop a WT. According to our own molecular
analysis of 64 WT patients, WT1 nonsense mutations are present
preferentially in patients with stromal-predominant or triphasic
Wilms’ tumors and most of these are present in the germline [36].
Four Wilms’ tumor patients of our series presented with hypo-
spadias and/or cryptorchidism and one had slight proteinuria, but
did not develop overt kidney disease and was therefore not
counted as a DDS patient. It is of interest that the splice site
mutation found in this child leads to a protein truncation in exon
7 at a similar site as in two other DDS patients, making it at least
possible that these children may not have DDS [11]. In fact our
own patient with the exon 6 mutation was initially described as a
Fig. 4. Glomerulus from a patient with genetically verified Denys-Drash syndrome (DDS). Panels were photographed at 3170. The glomerulus is
labeled with a arrow and the matrix expansion with a arrowhead.
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possible case of DDS [40], but further analysis revealed that the
patient did not have NS with ESRD [36] and it is now erroneously
listed as a DDS patient in [11]. All Wilms’ tumors from our DDS
patients were also either triphasic or stromal-predominant, sug-
gesting that germline mutations irrespective of the type (missense/
nonsense) lead to the development of stromal-predominant or
triphasic Wilms’ tumors. However, for the development of a WT
a second hit is needed that does not always occur, although the
risk to develop a Wilms’ tumor is over 90%, when a germline
missense mutation is present [38].
Genital anomalies were observed in all our seven DDS patients
with WT1 mutations who had a male karyotype, ranging from
severe forms of hypospadias, combined with a uterus and a vagina
in two to external female genitalia, combined with streak (hypo-
plastic) gonads. We hesitate to define these genital anomalies
generally as pseudohermaphroditism [41] as often reported in the
literature, because a pathoanatomical examination of the gonads
was not always performed in our series. The presence of germline
WT1 mutations in the ZF region is compatible with normal sexual
development in the female but not in the male. It seems that the
WT1 gene is involved in the molecular events leading to the
development of the male sex [12–14]. When the WT1DDS mutant
protein (protein with an amino acid exchange) is present during
the critical stage of sexual development it is thought to inhibit the
activity of the normal protein, resulting in genital anomalies. The
only exception is one apparently normal father with the hot spot
mutation [29]. In this case the father may have a complementing
mutation, abolishing the effect of the mutant protein, however,
this has never been observed in any other case. Besides other
possible explanations like genomic imprinting or mosaisism a mix
up of the samples should also be considered and excluded by
repeated sampling. In contrast, female DDS patients with the
same spectrum of WT1 mutations had a normal development of
external genitalia, while in one infant internal genitalia were
abnormal [17]. It is of interest that the male/female ratio of DDS
patients reported with WT1 mutations is increased to roughly 2:1.
On the basis of our observation of WT1 mutations in two females
with isolated infantile NS we assume that the genotypic females
are underrepresented among the DDS patients reported, because
the normal phenotype leads less frequently to a molecular analysis
of the WT1 gene.
The glomerulopathy in DDS has been thoroughly described
from a clinical and pathoanatomical point of view by Habib et al
[6, 42, 43]. Our 10 patients with WT1 mutations generally fit this
picture. Severe proteinuria was observed between the newborn
period and three years. In all patients renal failure was noted
concomitantly with NS. The time between onset of proteinuria
and ESRD was short (0–34 months). Interestingly, the longest
time was observed in the three male patients with a Wilms’ tumor
(complete DDS), however, with only three patients in this cate-
gory the significance of this observation needs confirmation by
analyzing more patients. The pathoanatomical diagnosis was
compatible with DMS in all children with WT1 mutations except
two infants with focal segmental glomerulosclerosis. FSGS has
been described in a few other patients with DDS although no
molecular genetic studies were described these patients [4]. In
comparison in our patients without WT1 mutations had an earlier
onset of proteinuria (birth to 4 months), but the time from onset
to ESRD tended to be shorter in the group with WT1 mutations.
At present it is difficult to decide if this difference in the rate of
progression is characteristic for WT1 associated nephropathy or is
simply due to a different patient selection. The group without
mutations was characterized by a high frequency of familial NS (5
of 7 patients) and of extrarenal/extragenital anomalies (5 of 7
patients) compared to the 10 patients with WT1 mutations. We
have not tested if the patients with familial NS without a WT1
mutation were linked to the previously described SRN1 locus on
chromosome 1 [44].
Based on our data and previous findings of WT1 mutations in
DDS patients, we propose that the presence of a WT1 germline
missense mutation and a nephrotic syndrome followed by rapid
progression to ESRD should suffice to define DDS. We propose
to abandon the division into complete and incomplete DDS and
isolated NS in the future and classify all these patients with WT1
missense mutations as DDS.
In conclusion, we suggest that patients with progressive forms
of early onset NS, even in absence of renal biopsy, should undergo
analysis of the WT1 gene independent on the finding of a WT or
genital abnormalities. The presence of DMS makes this research
mandatory. In males, ambiguous genitalia are an important
indicator of WT1 mutations. In females progressive glomerular
disease alone may be revealing. In about half of patients with
DDS no kidney tumor is recognized when NS becomes manifest.
WT1 mutations may be found in children presenting with NS or
renal failure after one year of age and in infants without DMS;
however, investigators are invited to provide more detailed mor-
phological description of renal histology from patients with WT1
mutations in the future. The finding of a missense mutation in the
WT1 gene indicates an increased risk to develop Wilms’ tumor
and possibly gonadoblastomas in later life, even after start of renal
replacement therapy. Therefore, careful monitoring of all patients
with WT1 mutations is required. Regular renal imaging may be
necessary to evaluate the need for bilateral nephrectomy in
patients with WT1 missense mutations who have attained ESRD.
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